CompletedPhase 2NCT03899805
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Studying Pleomorphic liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Suzanne George, MDDana-Farber Cancer Institute
- Intervention
- Eribulin(drug)
- Enrollment
- 57 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (2)
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03899805 on ClinicalTrials.govOther trials for Pleomorphic liposarcoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT02923778Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgeryNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT02275286Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma PatientsGrupo Espanol de Investigacion en Sarcomas